^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cudarolimab (IBI101)

    i
    Other names: IBI101, IBI 101
    Associations

    News

    Trials
    Company:
    Innovent Biologics
    Drug class:
    OX40 agonist
    Related drugs:
    Associations

    News

    Trials
    over4years
    Development and characterization of a novel anti-OX40 antibody for potent immune activation. (PubMed, Cancer Immunol Immunother)
    Recently, several anti-OX40 agonistic monoclonal antibodies, pogalizumab as the most advanced, have entered early phase clinical trials. Preclinical studies of IBI101 in non-human primates demonstrate typical pharmacokinetic characteristics of an IgG antibody and no drug-related toxicity. Collectively, IBI101 has desirable preclinical attributes which support its clinical development for cancer treatment.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    cudarolimab (IBI101) • pogalizumab (MOXR0916)